OPL-002

OPL-002 is a highly selective, orally bioavailable small molecule modulator of the sphingosine 1-phosphate receptor subtype 1 (S1P1). Developed by Oppilan Pharma, it is currently in clinical development for the treatment of moderate-to-severe ulcerative colitis and other inflammatory bowel diseases. The drug's mechanism involves sequestering lymphocytes within lymph nodes, which reduces the number of circulating immune cells available to drive inflammatory responses in the digestive tract. OPL-002 is designed to have low central nervous system (CNS) penetration and minimal ocular distribution, which may lead to a reduced risk of adverse effects such as liver injury and macular edema compared to other S1P modulators. Additionally, it lacks CYP450 interactions and active metabolites, potentially minimizing drug-drug interaction risks.